Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

ClinicalTrials.gov ID: NCT00644332

Public ClinicalTrials.gov record NCT00644332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

According to the American Heart Association (AHA) 2011 update of heart disease and stroke statistics, more than 9 million adult patients in the United States (US) have angina. This update also notes that a study of 4 national cross-sectional health examination studies found that, among Americans 40 to 74 years of age, the age-adjusted prevalence of angina was higher among women than men. Per ACC/AHA guidelines, the goal of antianginal therapy is the complete or near complete elimination of anginal chest pain and a return to normal activities and functional capacity. However, evaluating angina and responses to antianginal therapy is often not straightforward. This is particularly true of female patients with angina. Because angina and response to antianginal therapy may differ in men and women, an instrument designed specifically to address symptomatology in women with angina could enhance our understanding and characterization of angina and responses to therapy in this population. The current study will evaluate the validity, reliability, and responsiveness of the newly developed Women's Ischemia Symptom Questionnaire (WISQ) based on changes in angina symptomatology in a female angina population treated with ranolazine, compared with the widely used Seattle Angina Questionnaire (SAQ).

Study identification

NCT ID
NCT00644332
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Gilead Sciences
Industry
Enrollment
172 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Dec 31, 2010
Completion
Dec 31, 2010
Last update posted
Jul 1, 2012

2007 – 2011

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
The University of Alabama at Birmingham Birmingham Alabama 35294-0007
Cardiovascular Consultants, Ltd. Phoenix Arizona 85032
Cardiology Consultants of Orange County Anaheim California 92801
Access Clinical Trials/Cardiovascular Research Institute (ACT/CVRI) Beverly Hills California 90210
Escondido Cardiology Associates Escondido California 92025
Cedars-Sinai Medical Center Los Angeles California 90048
Mission Internal Medical Group Mission Viejo California 92691
South Denver Cardiology Associates, PC Littleton Colorado 80120-5654
Guerra Cardiology Coral Gables Florida 33134
Jacksonville Center for Clinical Research Jacksonville Florida 32216
St. Luke Cardiology Associates Jacksonville Florida 32216
Jacksonville Heart Center, PA Jacksonville Florida 32250
Jacksonville Heart Center, PA Jacksonville Florida 32258
Emory University & Grady Health System Atlanta Georgia 30303
Mercy Physician Group Cardiology Nampa Idaho 83686
North Shore Cardiology Bannockburn Illinois 60015
Gateway Cardiology, P.C. Jerseyville Illinois 62052
Northern Indiana Research Alliance Fort Wayne Indiana 46804
Ashland Hospital Corporation d/b/a King's Daughters Medical Center Ashland Kentucky 41101
University of Louisville, Division of Cardiovascular Medicine Louisville Kentucky 40202
Gateway Cardiology, P.C. St Louis Missouri 63128
Integrated Cardiology Consultants, LLC d.b.a. Bryan LGH Heart Institute Lincoln Nebraska 68506
Albany Associates in Cardiology Albany New York 12205
Total Heart Care, PC New York New York 10128
The Lindner Clinical Trial Center Cincinnati Ohio 45219
St. Vincent Mercy Medical Center, Cardiac Research Toledo Ohio 43608
BlueStem Cardiology Bartlesville Oklahoma 74006
Tri-State Medical Group, Cardiology, Sewickley Valley Medical Group, Cardiology Beaver Pennsylvania 15009
Cardiology Consultants of Philadelphia Philadelphia Pennsylvania 19111

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00644332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 1, 2012 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00644332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →